Clinical Trials

Unresectable Locally Advanced or Metastatic Extrapulmonary Neuroendocrine Carcinomas

NCT03604198 2026-04-21

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

125 enrolled

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Cushing Syndrome, Diabetes Mellitus, Type 2, Hypertension, Adrenocortical Carcinoma, Pituitary ACTH Hypersecretion

NCT02174549 2026-04-20

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

25 enrolled

Hypoxia, Carcinoma, Hepatocellular, Neuroendocrine Tumors

NCT05884255 2026-04-17

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

220 enrolled

Advanced Gastroenteropancreatic Neuroendocrine Tumor

NCT06943755 2026-04-17

STELLAR-311

Phase 2/3 Recruiting

440 enrolled

Adenoma, Islet Cell, Neoplasm Metastasis, Neuroendocrine Tumors

NCT03157128 2026-04-16

LIBRETTO-001

857 enrolled 24 charts 6 FDA

BreastCNSEndocrineGastrointestinalHead & NeckThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Central Nervous System Neoplasms, Carcinoma, Medullary

NCT06784752 2026-04-16

NETTER-3

EndocrineGastrointestinalLymphoidNET

240 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Follicular

NCT05153772 2026-04-15

ALPHAMEDIX02

69 enrolled

Neuroendocrine Tumors

NCT06502977 2026-04-15

DeLLphi-307

32 enrolled 9 charts

Neoplasms, Neuroendocrine Tumors

NCT05142189 2026-04-14

LuCa-MERIT-1

320 enrolled

BreastDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

NCT04924075 2026-04-13

MK-6482-015

Phase 2 Recruiting

322 enrolled 2 FDA

CNSEndocrine

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT05461430 2026-04-13

TraveraRTGx

Completed

72 enrolled

Anus Neoplasms, Appendiceal Neoplasms, Ascites, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Laryngeal Neoplasms, Lung Neoplasms, Melanoma, Mesothelioma, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasms, Unknown Primary, Oropharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Penile Neoplasms, Stomach Neoplasms, Thymoma, Vulvar Neoplasms, Pleural Effusion, Malignant, Carcinoma, Neuroendocrine, Cholangiocarcinoma, Carcinoma, Small Cell, Carcinoma, Pancreatic Ductal, Gastrointestinal Stromal Tumors

NCT07165132 2026-04-13

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

104 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT07278479 2026-04-08

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

138 enrolled

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT05631795 2026-04-07

ALPINIST

Phase 4 Completed

40 enrolled

Phase 3 Active not recruiting

Multiple Endocrine Neoplasia Type 1

NCT03049189 2026-04-06

COMPETE

324 enrolled 15 charts

Neuroendocrine Tumors

NCT06709040 2026-04-06

A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters

Enrolling by invitation

500 enrolled

Diabetes Mellitus, Type 2, Dwarfism, Pituitary, Neoplasms

NCT03093116 2026-04-03

TRIDENT-1

EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

500 enrolled 4 FDA

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colonic Neoplasms, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Neuroectodermal Tumors, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT07314164 2026-04-01

Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment

Recruiting

150 enrolled

Phase 1 Not yet recruiting

Neuroendocrine Tumors

NCT07488923 2026-04-01

SPECTRAL-1

110 enrolled

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT05477576 2026-03-30

ACTION-1

338 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT07377487 2026-03-30

INDIGO

Phase NA Recruiting

51 enrolled

Carcinoma, Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Colorectal Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT02650401 2026-03-25

STARTRK-NG

CNSEndocrineGenitourinaryHead & NeckSarcoma

69 enrolled 2 FDA

Thyroid Cancer, Papillary, Brain Neoplasms, Glioma, Medulloblastoma, Neoplasm Metastasis, Wilms Tumor, Neuroblastoma, Recurrence, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Ewing, Central Nervous System Neoplasms, Nephroma, Mesoblastic

NCT05680922 2026-03-24

DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

Phase 1 Active not recruiting

41 enrolled

EndocrineNETThoracic

Small Cell Lung Cancer Extensive Stage

NCT04727723 2026-03-20

REAL-LU

Active not recruiting

164 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT05361668 2026-03-19

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Phase 2 Completed

36 enrolled 19 charts

Phase 1 Active not recruiting

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

NCT06379217 2026-03-11

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

31 enrolled

EndocrineGenitourinary

Metastatic Neuroendocrine Prostate Cancer

NCT07087054 2026-03-10

CAREFNDR

141 enrolled

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

NCT07129252 2026-03-10

BRAVESST2

150 enrolled

Neoplasm Metastasis, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT02568267 2026-03-06

STARTRK-2

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

534 enrolled 1 FDA

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Phase 2 Completed

20 enrolled

CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

NCT04895748 2026-03-03

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Phase 1 Terminated

40 enrolled

CNSEndocrineGenitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma

NCT06910657 2026-03-02

IDOV-Immune for Advanced Solid Tumors

BreastDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

78 enrolled

Adrenal Gland Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Vaccinia, Colorectal Neoplasms

NCT03833700 2026-02-27

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

Phase 1 Active not recruiting

70 enrolled

EndocrineGastrointestinalNETSarcoma

Gastro-enteropancreatic neuroendocrine tumor, Digestive System Neoplasms, Carcinoma, Hepatocellular, Colorectal Neoplasms, Desmoid Tumors, Adrenocortical Carcinoma

NCT07282587 2026-02-27

Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma

Phase 2 Recruiting

90 enrolled

CNSEndocrine

Paraganglioma

NCT04471727 2026-02-24

MK-6070-001

EndocrineGenitourinaryNETThoracic

232 enrolled

Lung Neoplasms, Prostatic Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT07189403 2026-02-24

A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer

40 enrolled

Phase 3 Active not recruiting

Adrenocortical Carcinoma

NCT03194893 2026-02-20

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

200 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms, Multiple Endocrine Neoplasia Type 2a

NCT06542237 2026-02-13

Open Label, Dose Escalation, Repeat Dose Study Evaluating YCT-529 in Healthy Males

88 enrolled

Multiple Endocrine Neoplasia Type 1

NCT04711135 2026-02-12

NETTER-P

11 enrolled 14 charts 2 FDA

CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT07080242 2026-02-09

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

120 enrolled

Neoplasm Metastasis, Carcinoma, Neuroendocrine

NCT04187404 2026-01-30

Spencer

Phase 1/2 Terminated

70 enrolled 20 charts

CNSEndocrine

Paraganglioma, Pheochromocytoma, Adrenocortical Carcinoma

NCT06055439 2026-01-29

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

135 enrolled

Phase NA Active not recruiting

Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors

NCT06620419 2026-01-27

Clinical Study of External Electrical Stimulation for Male Incontinence

30 enrolled

Urinary Incontinence, Multiple Endocrine Neoplasia Type 1

NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

EndocrineGastrointestinalGenitourinaryNET

27 enrolled

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

NCT07174583 2026-01-23

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

208 enrolled

BreastEndocrineGastrointestinalGenitourinaryNET

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT04373564 2026-01-22

ODYSSEY

Phase 4 Recruiting

2,076 enrolled

Breast Neoplasms, Carcinoma, Hepatocellular, Prostatic Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors

NCT03972488 2026-01-21

NETTER-2

Phase 3 Active not recruiting

226 enrolled 14 charts

BreastDermatologicEndocrineGynecologicHead & Neck

Gastro-enteropancreatic neuroendocrine tumor

NCT03746431 2026-01-07

A Phase 1 Study of [225Ac]-FPI-1434 Injection

Phase 1 Terminated

78 enrolled

Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Adrenocortical Carcinoma, Triple Negative Breast Neoplasms

NCT03899792 2026-01-06

LIBRETTO-121